Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The appointment of a new top executive clearly meets with investor approval.

Why Inovio Pharmaceuticals Stock Topped the Market on Monday

PLYMOUTH MEETING, Pa. , June 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer (CMO).

INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer

Abbott Labs

Chimerix

Emergent BioSolutions

SIGA Technologies

Tonix Pharmaceuticals Hld

SIGA Technologies (SIGA) may lead on the list of monkeypox stocks that could soar, but Bavarian Nordic seems to be leading the sales race. The post 7 Monkeypox Stocks That May Take Off in Q2 appeared first on InvestorPlace.

7 Monkeypox Stocks That May Take Off in Q2

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Jefferies 2022 Global Healthcare Conference June 8, 2022 1:00 PM ET Company Participants Jacqui Shea - CEO Jeffrey Skolnik - CMO Conference Call Participants Roger Song - Jefferies Roger Song Good afternoon, everyone. Welcome to Jefferies Global Healthcare Conference day one afternoon.

Inovio Pharmaceuticals, Inc. (INO) CEO Jacqui Shea Present at Jefferies 2022 Global Healthcare Conference (Transcript)

Vaxart

Stock Market Plunge: 2 Stocks to Avoid Right Now

The stock price of INOVIO Pharmaceuticals Inc (NASDAQ: INO) increased by over 14% during intraday trading today. This is why.

INOVIO Pharmaceuticals (INO) Stock Price: Why It Rose Over 14% Today

Allarity Therapeutics

Avadel Pharma

BlackSky Technology

BitNile Holdings

Are these penny stocks to buy or avoid right now? The post Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR

INOVIO's DNA medicines immunotherapy in combination with Libtayo® elicits vaccine-associated immune responses when administered with RT/TMZ to newly diagnosed GBM patients INO-5401 + INO-9012 + Libtayo ®  elicits cancer antigen-specific T cells 55% of MGMT methylated subjects remain alive at a median of 32.5 months Dr. David Reardon, Principal Investigator, to present on June 6, 2022 at ASCO PLYMOUTH MEETING, Pa. , May 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced results from the company's novel Phase 1/2 trial of INO-5401 and INO-9012 in combination with PD-1 inhibitor Libtayo® (cemiplimab) in the treatment of newly diagnosed glioblastoma (GBM), including encouraging median overall survival (OS) data from fifty-two subjects.

INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022

Geovax Labs

Wondering what are the best monkeypox stocks to watch? Here are the companies producing vaccines to help fight the spread of the virus.

7 Monkeypox Stocks to Watch Right Now

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher Monday amid increasing monkeypox concerns.  A monkeypox outbreak has been reported in at least a dozen countries.

Why Inovio Pharmaceuticals Stock Is Rising Today

PLYMOUTH MEETING, Pa. , May 23, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced that Jacqueline Shea, Ph.D.

INOVIO to Present at Jefferies 2022 Healthcare Conference

A Monkeypox outbreak has been reported in several European countries, two cases in Canada and one confirmed case in a man from Massachusetts. What's going on?

6 Stocks To Watch Amid Monkeypox Outbreak

AstraZeneca

Johnson & Johnson

Moderna

Pfizer

Is This Vaccine Stock in Trouble -- or Ready for a Rebound?

Inovio Pharmaceuticals has halted its Covid-19 progress to focus on a booster. Here's why this news is unlikely to boost INO stock.

INO Stock Plunges 25% as Inovio Pharmaceuticals Swaps Vaccine Focus

Inovio Pharmaceuticals Inc.'s INO, +5.06% stock tumbled 21.7% in premarket trading on Wednesday, the day after the company said it will discontinue its work on a COVID-19 vaccine and will instead focus only on developing a booster. Inovio also said it has replaced CEO Joseph Kim.

Inovio lets go of CEO, to stop work on COVID-19 vaccine and instead focus on booster

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Ben Matone - Director, IR Jacqueline Shea - COO Dave Liebowitz - SVP, Clinical Development for Infectious Diseases Jeffrey Skolnik - SVP of Clinical Development for Oncology and HPV Therapeutics Peter Kies - CFO Conference Call Participants Hartaj Singh - Oppenheimer Roger Song - Jefferies Yi Chen - H.C. Wainwright & Co. Operator Good afternoon, and welcome to the Inovio Pharmaceuticals First Quarter 2022 Financial Results Conference Call.

Inovio Pharmaceuticals, Inc. (INO) on Q1 2022 Results - Earnings Call Transcript

Inovio (INO) delivered earnings and revenue surprises of -28.57% and 56.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Inovio Pharmaceuticals (INO) Reports Q1 Loss, Lags Revenue Estimates

Announces prioritization of heterologous booster strategy for COVID-19 vaccine candidate INO-4800 and discontinuation of Phase 3 INNOVATE trial to optimize potential impact on global public health Reports, with partner Advaccine, positive T cell immune response data with INO-4800 as a heterologous booster to an inactivated COVID-19 vaccine Announces change in plans for VGX-3100 following input from FDA on need for additional trials for a marketing application for the treatment of HPV-associated cervical high-grade squamous intraepithelial lesions Announces appointment of Jacqueline Shea, Ph.D. as CEO Will hold investor call today at 4:30 PM EDT PLYMOUTH MEETING, Pa.

INOVIO Reports First Quarter 2022 Financial Results and Program Developments

Dr. Shea brings more than 25 years of leadership and industry expertise in life sciences and biotech PLYMOUTH MEETING, Pa., May 10, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Jacqueline Shea, Ph.D.

INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer

PLYMOUTH MEETING, Pa. , April 26, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that first quarter 2022 financial results will be released after the market close on May 10, 2022.

INOVIO to Report First Quarter 2022 Financial Results on May 10, 2022

Babylon Holdings Ltd

Hippo Holdings

Liberty Media Corp-Liberty SiriusXM

Orchid Island Capital

Qurate Retail Inc

REE Automotive Ltd

It's a new market, and not every bargain is an opportunity to jump in. The post 7 F-Rated Penny Stocks Not Worth the Gamble appeared first on InvestorPlace.

7 F-Rated Penny Stocks Not Worth the Gamble

These two companies have been left in the dust. Is it too late for them?

2 Contenders in the Coronavirus Vaccine Market -- Are They Buys?

Primary and secondary endpoints met in late-stage REVEAL 1 which used VGX-3100 for women with HSIL. Results form the second late-stage study REVEAL 2, using VGX-3100 for women with HSIL, expected in Q4 of 2022.

Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022

Geneos expands its Phase Ib/IIa clinical trial in lead indication for treating patients with advanced hepatocellular carcinoma Financing led by Flerie Invest and Dr. Ted Fjällman joins Geneos' Board of Directors PLYMOUTH MEETING, Pa. , March 24, 2022 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of tumor neoantigen targeted personalized immunotherapies, announced today that it has secured $17 million in Series A2 financing.

Geneos Therapeutics Secures $17 Million in Series A2 Financing to Advance Personalized Cancer Immunotherapy Platform

iQIYI

2 Beaten-Down Stocks That Aren't Worth the Trouble

News for Inovio Pharmaceuticals Stock (INO)